Artiklar: Response: A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield G, et al. N Eng J Med. 2024; 390(9):783-794
Prevalens:
Lv T, et al. J Gastroenterol Hepatol 2021;36(6):1423-1434
Marschall HU, Henriksson I, Lindberg S, Söderdahl F, Thuresson M, Wahlin S, Ludvigsson JF. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep. 2019;9(1):11525
Symtom:
Mells GF, et al. Hepatology 2013;58(1):273-283
Onofrio FQ, et al. Gastroenterol Hepatol (NY) 2019;15(3):145-154
Mayo MJ, et al. Dig Dis Sci 2023;68(3):995-1005
Selmi C, et al. Hepatology 2007;46(6):1836-1843
Hirschfield G, et al. N Eng J Med. 2024; 390(9):783-794
Mayo MJ, et al. Dig Dis Sci 2023;68(3):995-1005
PBC patogenes:
Gulamhusein et al. Nat Rev Gastroenterol Hepatol. 2020; 17(2):93-110.
Kontakta oss
Kontakta våra sälj- och medicinska team
Har du frågor om våra läkemedel eller produkter? Kontakta oss.
